[HTML][HTML] Advances in rodent models for breast cancer formation, progression, and therapeutic testing
C Liu, P Wu, A Zhang, X Mao - Frontiers in Oncology, 2021 - frontiersin.org
Breast cancer is a highly complicated disease. Advancement in the treatment and
prevention of breast cancer lies in elucidation of the mechanism of carcinogenesis and …
prevention of breast cancer lies in elucidation of the mechanism of carcinogenesis and …
Single-Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Breast Cancer in BRCA1 Mutation Carriers
L Hu, L Su, H Cheng, C Mo, T Ouyang, J Li, T Wang… - Cancer research, 2021 - AACR
The cell of origin and the development of breast cancer are not fully elucidated in BRCA1
mutation carriers, especially for estrogen receptor (ER)–positive breast cancers. Here, we …
mutation carriers, especially for estrogen receptor (ER)–positive breast cancers. Here, we …
[HTML][HTML] FANCM regulates repair pathway choice at stalled replication forks
Repair pathway" choice" at stalled mammalian replication forks is an important determinant
of genome stability; however, the underlying mechanisms are poorly understood. FANCM …
of genome stability; however, the underlying mechanisms are poorly understood. FANCM …
[HTML][HTML] Models of pancreatic ductal adenocarcinoma
Although pancreatic cancer remains to be a leading cause of cancer-related deaths in many
industrialized countries, there have been major advances in research over the past two …
industrialized countries, there have been major advances in research over the past two …
[HTML][HTML] Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform
The feasibility of personalized medicine for cancer treatment is largely hampered by costly,
labor-intensive and time-consuming models for drug discovery. Herein, establishing new pre …
labor-intensive and time-consuming models for drug discovery. Herein, establishing new pre …
Activation of FGFR2 signaling suppresses BRCA1 and drives triple‐negative mammary tumorigenesis that is sensitive to immunotherapy
Fibroblast growth factor receptor 2 (FGFR2) is a membrane‐spanning tyrosine kinase that
mediates FGF signaling. Various FGFR2 alterations are detected in breast cancer, yet it …
mediates FGF signaling. Various FGFR2 alterations are detected in breast cancer, yet it …
[HTML][HTML] A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma
Kras-driven lung adenocarcinoma (LUAD) is the most common lung cancer. A significant
fraction of patients with Kras-driven LUAD respond to immunotherapy, but mechanistic …
fraction of patients with Kras-driven LUAD respond to immunotherapy, but mechanistic …
Two redundant ubiquitin‐dependent pathways of BRCA1 localization to DNA damage sites
A Sherker, N Chaudhary, S Adam, AM Heijink… - EMBO …, 2021 - embopress.org
The tumor suppressor BRCA1 accumulates at sites of DNA damage in a ubiquitin‐
dependent manner. In this work, we revisit the role of RAP80 in promoting BRCA1 …
dependent manner. In this work, we revisit the role of RAP80 in promoting BRCA1 …
[HTML][HTML] PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors
F Bai, S Liu, X Liu, DP Hollern, A Scott, C Wang… - Breast Cancer …, 2021 - Springer
Background Basal-like breast cancers (BLBCs) are a leading cause of cancer death due to
their capacity to metastasize and lack of effective therapies. More than half of BLBCs have a …
their capacity to metastasize and lack of effective therapies. More than half of BLBCs have a …
Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants
G Ruiz de Garibay, I Fernandez‐Garcia… - Human …, 2021 - Wiley Online Library
Germline pathogenic variants in BRCA1 confer a high risk of developing breast and ovarian
cancer. The BRCA1 exon 11 (formally exon 10) is one of the largest exons and codes for the …
cancer. The BRCA1 exon 11 (formally exon 10) is one of the largest exons and codes for the …